February 16, 2022

February 16, 2022

Surviving Chernobyl: The Incredible Story of Dr. Yan Leyfman

While not a CLL story, Dr. Yan Leyfman is one of the few survivors of radiation poisoning from Chernobyl in the former Soviet Union. He shares his amazing story about his family’s advocating for his care, including leaving his homeland to get medal care.

February 16, 2022

Dr. Leyfman Discusses the Increased risk of COVID-19 and Cancer Patients

Dr. Leyfman discusses three medications that he hopes will prove to help with COVID-19

February 16, 2022

Cancer and COVID-19: A Proposed Mechanism with Therapeutic Interventions

In our second interview, Dr. Leyfman shared his research on COVID-19 and cancer patients presented at the American Society of Clinical Oncology’s Annual Meeting or ASCO 2021. He discussed a radically different approach with an experimental cellular therapy, mesenchymal stem cells, which demonstrated a 91% overall survival and 100%

February 16, 2022

ASH 2021: A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients

This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) reported analysis of retrospective data from 91 adult patients in France with lymphoma or chronic lymphocytic leukemia (CLL) who enrolled in a study of antibody responses, measured two or more weeks after receiving second or

February 16, 2022

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients without the high-risk mutation,17p deletion

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

February 16, 2022

Surviving Chernobyl: The Incredible Story of Dr. Yan Leyfman

Dr. Leyfman Discusses the Increased risk of COVID-19 and Cancer Patients

Cancer and COVID-19: A Proposed Mechanism with Therapeutic Interventions

ASH 2021: A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT